Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com 3 Undervalued Names Too Cheap to IgnoreAuthored by Nathan Reiff. First Published: 3/7/2026. 
Key Takeaways - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with value metrics that are historically low and/or competitive versus peers or the broader market. They also offer added benefits, including compelling dividends or promising new product developments. While value opportunities can be harder to find when many high-potential companies have already attracted investor attention—or when apparent bargains have deteriorating operations—well-established, stable names can also present attractive value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works The gold trade Wall Street won't tell you about (before March 18) Most investment banks now predict gold will cross $10,000 an ounce. But the smartest way to profit has nothing to do with bullion, ETFs, or mining stocks. There's an overlooked approach that turned every $5,000 invested into more than $1.6 million during one historic gold rally - and the next surge could begin as early as March 18. Click here to see our full March 18 gold prediction - right here - absolutely FREE. Although shares have climbed more than 28% over the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45, well below the medical industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% in the coming year and has a 5% near-term upside. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received European Commission approval for subcutaneous injection in late 2025 and generated about $8.4 billion in sales in Q4 2025, up nearly 7% year over year. Keytruda also shows promise in ovarian cancer, potentially expanding its patient base. These trends should help Merck grow revenue as it prepares for Keytruda's patent expiration in 2028. Merck's broader pipeline is also expanding, including recent phase 3 results for clesrovimab-cfor (Enflonsia), an RSV treatment for young children. At the same time, the company is making strategic moves ahead of Keytruda's patent loss, splitting its human health division into two units to more easily diversify and increase non-cancer-drug sales. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell’s (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple has faced pressure from tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company reported modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share (EPS) fell 13%. The company has not yet seen notable margin improvement following its cost-saving measures. The near term will likely remain challenging for the iconic brand, as fiscal-year guidance is weak overall. However, an improving supply chain and strong brand loyalty—especially for premium offerings—should help protect the business. Changes in tariff policy could also ease some of the external pressure the company faces. On the upside, Campbell's remains a compelling dividend play, with an attractive yield of 5.9%, though its payout ratio is fairly high at more than 80%. Additionally, Campbell's P/E ratio of 13.5 is the lowest in about four years. These factors could convince some investors that the stock is worth the risk despite Wall Street caution. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has charted an almost opposite course to Campbell's—in the last year, shares have climbed about 33%. Even after the rally, its P/E ratio sits at 31.6. On the fundamentals, US Foods is making meaningful strides: the company reported improving profitability in the latest quarter and posted full-year adjusted EBITDA gains of 11% year over year. Stronger inventory management and cost-of-goods improvements are helping the firm gain traction. With a $4 billion capital deployment plan, US Foods is well positioned to maintain revenue growth momentum and continue expanding adjusted EBITDA. Analysts view USFD as a Moderate Buy based on 11 Buys and 2 Holds, implying roughly 15% upside potential.
| 
